ALK inhibitor
Anaplastic lymphoma kinase inhibitor
- Suppresses growth of ALK-fusion–driven lung cancer
- Kinase-domain resistance mutations → acquired resistance
- Targets ALK-rearranged non-small cell lung cancer
- Resistance emerges through kinase-domain mutations
Drugs with this mechanism (4)
- Alectinib — ALK inhibitor with strong CNS activity; preferred first-line therapy for ALK-positive lung cancer.
- Ceritinib — ALK inhibitor for ALK-positive lung cancer.
- Crizotinib — First ALK inhibitor; poor CNS penetration is why later agents replaced it.
- Lorlatinib — Third-generation ALK inhibitor built for CNS penetration; causes distinctive CNS effects.
All mechanisms · Open ALK inhibitor in the interactive console ↗